| Hans-Günter Meyer-Thompson | Legal
USA. Indivior Responds to Generic SUBOXONE® Approvals and Dr. Reddy’s Launch “At-Risk”
USA. Indivior Responds to Generic SUBOXONE® Approvals and Dr. Reddy’s Launch “At-Risk”
Indivior PLC (LON: INDV) (“Indivior” or the “Company”) today announced that it is aware that, on 14 June 2018, the US FDA approved generic versions of SUBOXONE® Film from both Dr. Reddy’s and Mylan, and that Dr. Reddy’s subsequently announced it has launched its generic buprenorphine/naloxone sublingual film product “at-risk” in the US. (Indivior, UK, 15.06.2018)